Thomas Klustermann is a clinical neuroscientist who is currently working on the development of biomarkers for Parkinson’s Disease (PD), neuropsychiatric and neurodevelopment disorders. Previously, he worked on identifying biomarkers for outcome prediction in comatose patients, linked to survival rates. In his current position at Roche, Dr. Klusterman leads the biomarker strategy for the clinical-stage drug Prasinezumab, which is currently being evaluated in multiple phase 2 clinical trials. In this position, he is responsible for the development, implementation and analysis of biomarkers in clinical trials as well as the development of novel biomarkers to support the understanding of disease biology, progression and potential drug effects. He collaborates with leading disease biology and clinical experts to develop, validate and implement biomarkers that allow for enhanced diagnosis, monitoring of disease progression and of potential treatment effects.
Using the Chemical Modification of Alpha-synuclein to Define Disease State and Facilitate Patient Stratification in Parkinson’s Disease